Compare Gold Fields Limited (GFI) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Heron Therapeutics Inc — how do they compare? Gold Fields Limited trades at $37.31 (market cap $31.87B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: Gold Fields Limited is far larger — about 468.6× Heron Therapeutics Inc's market cap, and Gold Fields Limited pays a 6% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Heron Therapeutics Inc for 35 Days on average.
| GFI | HRTX | |
|---|---|---|
Market Cap | $31.87B | $68.01M |
Volume | 4,169,651 | 1,891,941 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $1.49 |
52-Week Low | $31.25 | $0.27 |
Typical Hold Time | 49 Days | 35 Days |
Enterprise Value | $32.47B | $174.75M |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.05, down 3.1% amid market reaction to its rejected $27 billion bid for Northern Star. The stock shows a bearish technical signal with key support at $34-$35, while fundamentals remain strong with a 40.76% net margin and low P/E of 7.3. Recent earnings saw mixed results, with one beat and three misses against expectations.
The outlook is balanced: robust cash flow and high profitability support upside toward the $52.75 analyst target, but acquisition uncertainty and technical weakness pose near-term risks. Investor sentiment is cautious pending clarity on M&A strategy and capital allocation.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
